Alkermes announces FDA acceptance for review of NDA for ALKS 5461 for reatment of MDD
Alkermes announced the FDA has accepted for review the NDA for ALKS 5461, a novel, once-daily, oral investigational medicine for the adjunctive treatment of major depressive disorderin patients with an inadequate response to standard antidepressant therapies. April 16, 2018